The most studied interleukin is perhaps IL-6, given that tocilizumab, a monoclonal antibody directed against the IL-6 receptor, can be used as therapy for COVID-19 patients who present signs of hyperinflammation. The gene discussed is IL6; the disease is COVID-19.